A multicentre, prospective, real-world cohort study assessing the impact of Selexipag and other Pulmonary Arterial Hypertension (Pah) Therapies and its safety profile
Latest Information Update: 08 Oct 2022
At a glance
- Drugs Selexipag (Primary) ; Antihypertensives
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms EXPOSURE
Most Recent Events
- 29 Aug 2022 Results (n=382; as of Nov 2020) reporting outcomes during selexipag exposure method presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 29 Aug 2022 Results (n=1588; Between September 2017 and November 2021) assessing the clinical characteristics, treatment patterns and outcomes of pulmonary arterial hypertension associated with congenital heart disease patients in current clinical practice, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
- 19 May 2021 Results (Data cut off date June 2020, n=300) of EXPOSURE observational study assessing Selexipag Titration and Dosing Patterns in Patients with Pulmonary Arterial Hypertension (PAH) presented at the 117th International Conference of the American Thoracic Society